Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis

oleh: Alan H. Bryce, Rhett P. Ketterling, Morie A. Gertz, Martha Lacy, Ryan A. Knudson, Steven Zeldenrust, Shaji Kumar, Suzanne Hayman, Francis Buadi, Robert A. Kyle, Philip R. Greipp, John A. Lust, Stephen Russell, S. Vincent Rajkumar, Rafael Fonseca, Angela Dispenzieri

Format: Article
Diterbitkan: Ferrata Storti Foundation 2009-03-01

Deskripsi

Background Light chain amyloidosis is a rare plasma cell dyscrasia. Interphase fluorescence in situ hybridization (FISH) coupled to cytoplasmic staining of specific Ig (cIg-FISH) on bone marrow plasma cells has become well established in the initial evaluation of multiple myeloma, a related disorder. Little, however, is known about cytogenetic abnormalities in patients with light chain amyloidosis.Design and Methods We reviewed 56 patients with light chain amyloidosis who had cIg-FISH performed as part of their routine clinical testing using the standard screening panel employed in multiple myeloma at our institution.Results Seventy percent of patients had abnormal cIg-FISH, with the most common abnormalities being IgH translocations [48%] – including t(11;14) [39%], and t(14;16) [2%] – and del13/del13q [30%]. No t(4;14) or deletions of 17p (p53) were observed. Patients with t(11;14) had the lowest levels of clonal plasma cells, and those with del13 had the highest. The risk of death for patients harboring the t(11;14) translocation was 2.1 (CI 1.04–6.4), which on multivariate analysis was independent of therapy.Conclusions Although preliminary, our data would suggest that cIg-FISH testing is important in patients with light chain amyloidosis and that t(11;14) is an adverse prognostic factor in these patients.